Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Université de Montréal.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Université de Montréal
ClinicalTrials.gov Identifier:
NCT01168492
First received: July 21, 2010
Last updated: July 22, 2010
Last verified: July 2010

July 21, 2010
July 22, 2010
July 2010
July 2011   (final data collection date for primary outcome measure)
pain score [ Time Frame: after one year ] [ Designated as safety issue: No ]
pain scores are accorded at the end of each endoscopy. Pain scores of the two groups will be compared after one year
Same as current
Complete list of historical versions of study NCT01168492 on ClinicalTrials.gov Archive Site
necessity of cardiopulmonary intervention (Oxygen requirements) [ Time Frame: after one year ] [ Designated as safety issue: Yes ]
according to Observer'sAssessment of Alertness/Sedation (OAAS) score
Same as current
Not Provided
Not Provided
 
Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation
Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation

The purpose of this study is to determine whether ketamine, midazolam, and meperidine are more effective than midazolam and meperidine alone for procedural sedation and analgesia in pediatric digestive endoscopy. Secondary outcomes are the incidence of cardiorespiratory side effects and the necessity of rescue doses.

90 patients will be included. The sedation will include 0.1mg/kg, max 5mg iv of midazolam, 1mg/kg, max 50mg iv of meperidine, and placebo (0.9%NaCl) or ketamine 0.5mg/kg iv. Rescue doses will be given as usual, using meperidine and or midazolam 50% of the initial dose.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Pain
  • Conscious Sedation
Drug: ketamine
0.5mg/kg ketamine iv
Other Name: no other names
  • Experimental: ketamine
    group with triple sedation (ketamine, midazolam, meperidine)
    Intervention: Drug: ketamine
  • Placebo Comparator: placebo
    group with conventional sedation and placebo ( midazolam, meperidine and placebo)
    Intervention: Drug: ketamine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
December 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children =/> 10 years of age
  • Undergoing elective diagnostic colonoscopy
  • ASA score class 1-3.

Exclusion Criteria:

  • Children younger than 10 years of age
  • Known epilepsy under treatment
  • ASA score class 4 or more
  • Interventional colonoscopy (e.g.polypectomy)
Both
10 Years to 19 Years
No
Contact: Denise Herzog, MD 514 345-4931 ext 4626 deniseherzog@hotmail.com
Contact: Christophe Faure, MD 514 345-4931 ext 4626 christophe.faure@umontreal.ca
Canada
 
NCT01168492
cme#2857
No
Denise Herzog, University of Montreal
Université de Montréal
Not Provided
Principal Investigator: Denise Herzog, MD Université de Montréal
Université de Montréal
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP